Subjects with hyperaldosteronism, as well as subjects on chronic treatment with angiotensin-converting enzyme (ACE) blockers or angiotensin type 1 receptor antagonists, exhibit increased Aldo levels, an event known as “aldosterone breakthrough” [28]. This evidence concerns the gene ACE and hyperaldosteronism.